Myeloid differentiation primary response protein 88 (MyD88), a pivotal adaptor protein in the Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways4, has emerged as a promising candidate in the breast cancer research narrative. This evidence concerns the gene MYD88 and breast carcinoma.